Kivorent News

Wednesday, November 18, 2026

Health techNews

Remedy Robotics raises $62 million for remote stroke-treatment robot

Remedy Robotics, a San Francisco startup building an AI-guided robot for catheter procedures, raised a $62 million Series B led by DCVC to fund a pivotal trial with the University of California and work toward FDA approval.

Docket, covering health regulation and AI in care
, 3 min read

$62MSeries B led by DCVC, announced November 16

What to know

  • Remedy Robotics announced a $62 million Series B on November 16, led by DCVC with new investors UC Investments, Skip Capital and Hostplus.
  • The money funds a planned pivotal trial across the University of California network and work toward FDA approval for neurovascular procedures.
  • The company says its N1 System is investigational and not available for sale or clinical use in any jurisdiction.

Remedy Robotics, a San Francisco startup building a robot that can perform catheter-based heart and brain procedures, including from a remote location, has raised $62 million in a Series B round. The company announced the round on November 16. Venture firm DCVC led it.

New investors are UC Investments, the University of California's investment office; Skip Capital; and Hostplus, an Australian pension fund. Returning backers include Build Collective, the fund of iPod and Nest creator Tony Fadell, along with Blackbird, Divergent Capital and KdT Ventures. Remedy did not disclose a valuation or its total funding to date.

What the N1 System does

Remedy's product is the N1 System, a robotic platform with software for endovascular procedures, the minimally invasive treatments in which a doctor threads wires and catheters through blood vessels. Mechanical thrombectomy, which pulls a clot out of a brain artery after a stroke, is one of them.

According to the company, N1 uses machine learning on a patient's scans before the procedure, lets teams simulate the case, and lines up 3D images with live 2D X-ray video during the procedure. Remedy says it is designed to run on site, remotely, or with increasing autonomy, and it targets brain, coronary and peripheral blood vessel care. In October 2025 the company announced what it called the first remote neurointerventional procedures using N1.

The case Remedy makes is about access. Clot removal has to happen fast and needs specialists who mostly work at large stroke centers. The company's release cites a figure that only 2.8% of eligible stroke patients worldwide get endovascular treatment. A robot that a specialist could drive from another city is its proposed fix.

Where it stands with regulators

N1 is not approved. The release says the system is not currently available for sale or clinical use in any jurisdiction, and Securities.io notes that its safety and effectiveness have not been established. Remedy says the new money will fund a pivotal clinical trial run across the University of California network, the kind of study the FDA typically relies on for a high-risk device, and further work "toward FDA approval" for neurovascular intervention. It has not given the trial's size, design or start date, and it has not named any FDA submission.

The company also plans to place prototype N1 units with clinical partners, naming the SVIN Mission Thrombectomy program and the Australian Stroke Alliance, and to keep developing its AI and autonomy features. Securities.io reported that Remedy works with more than 100 hospitals worldwide; that figure comes from the company.

For how the FDA's routes to market differ, see our explainer on clearance, approval and De Novo. For what a pivotal trial can and cannot show, see what a randomized controlled trial can tell you.

Why it matters

Stroke care is where AI in medicine has gone furthest so far, mostly as software that flags blockages or aneurysms on scans, such as the Bracco and Avicenna.AI aneurysm tool cleared this month. Remedy is betting on the next step: a machine that helps perform the treatment, possibly with the doctor in another building. The University of California is both an investor and the planned trial site. That arrangement, and how much autonomy the FDA will accept in a robot working inside a patient's brain arteries, are the things to watch. Federal health agencies are also writing a policy push for AI in care, as in CMS's Clinical Super Intelligence roadmap.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

Digital health and AI in careFDA and health regulationHeart health tech

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.